|
|
Xoma licenses antibody technology to Pfizer (PharmaBiz)
Xoma Ltd. announced that it has licensed to Pfizer Inc., the world’s largest research-based biomedical and pharmaceutical company, non-exclusive, worldwide rights to Xoma’s patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products.
Hutchinson Technology “neutral,” target price raised (New Ratings)
NEW YORK, August 30 (newratings.com) - Analysts at Robert W Baird maintain their “neutral” rating on Hutchinson Technology ( HTCH.NAS ). The target price has been raised from $20 to $24.
Technology stocks power rebound in U.S. equities (International Herald Tribune)
U.S. stocks rebounded Wednesday from their steepest drop in three weeks after earnings prospects for technology companies improved and shares of energy producers advanced.